AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: Genentech (PERJETA) (perjeta.com)
This is a high-substance, low-fluff pharmaceutical site that prioritizes regulatory compliance and technical accuracy over marketing hyperbole. The BS score is driven almost entirely by a single emotional H1 and a technical schema flag regarding review counts. It represents the gold standard for substantive product-led medical communication.
Change the homepage H1 from ‘I’m all in’ to a descriptive technical heading such as ‘PERJETA Treatment for HER2+ Early and Metastatic Breast Cancer.’ Ensure the review_count in the schema_json is removed if it does not link to a verifiable third-party review platform. Include direct links to peer-reviewed ClinicalTrials.gov study results in the ‘Clinical Data’ or footer sections to maximize proof paths. Replace generic female patient icons with specific data visualizations of the PERJETA mechanism of action.
The information density is extremely high for the body text, though the primary H1 ‘I’m all in’ is a pure emotional power-word construct without a noun. The body text contains precise technical protocols, such as ‘initial dose of 840 mg infused over 60 minutes’ and specific household income thresholds for financial aid ($150,000). Specificity is maintained through technical nomenclature like ‘HER2-positive early breast cancer’ and ‘neoadjuvant treatment’ across all pages. The ratio of fluff to substance is negligible once past the hero section.
Most sites "have schema," but AI still cannot understand what their pages represent. Run a Structured Data AI Audit to see what entity types your pages actually resolve into.
Semantic drift is nearly non-existent; the homepage hero section promises a treatment path for HER2+ breast cancer which is then rigorously defined on the sub-pages. The sub-page for early breast cancer delivers exactly what the homepage navigation suggests, including a clear distinction between neoadjuvant and adjuvant treatment. There are no contradictions between the ‘Financial resources’ claim on the homepage and the detailed co-pay/assistance eligibility tables on the financial sub-page. The site transitions seamlessly from patient-centric emotional hooks to clinical data for HCPs.
Stop the ROI leak caused by technical debt and strategic misalignment. Conduct an Independent Strategic Diagnosis for 1 Euro to identify high impact issues across all audit categories.
The trust signals are mostly substantiated by regulatory requirements rather than marketing gimmicks. While the data shows a review_count of 1 with 0 external proof links, this is typical for pharma sites where ‘reviews’ are not allowed and ‘proof’ is provided by a link to the Full Prescribing Information. The presence of the FDA MedWatch reporting number (1-800-FDA-1088) acts as a high-authority proof path. The trust_theatre_flag is triggered by the structured data review count, which appears to be a technical placeholder rather than a substantive testimonial claim.
Proof density is high, with a ratio of approximately one clinical or logistical fact for every three sentences of marketing copy. Verifiable evidence includes specific clinical trial registration references implied by the Prescribing Information and the Genentech Patient Foundation income brackets. Vague assertions like ‘I’m all in’ are confined to the decorative H1s, while the actionable text remains data-driven. The site provides specific timeframes for enrollment (five business days) and claim submission (365 days) for financial aid.
To examine how structural entropy affects chunking and retrieval, review the Moz Semantic HTML audit. View the Moz Semantic HTML Audit for a complete example of heading logic, landmark integrity, and DOM depth diagnostics.
The value proposition is product-specific rather than industry-generic because it centers on a specific FDA-approved molecule (pertuzumab). While template elements like ‘Starting the conversation’ are standard for patient-facing pharma sites, the content within these blocks is highly specific to HER2+ therapy. The financial assistance section is uniquely detailed with specific program terms that could not be easily copy-pasted by a generic competitor. Clichés are present (e.g., ‘Discover another treatment’) but are subordinate to the technical mechanism of action.
There are no authority gaps as the site is backed by Genentech, a verifiable biotechnology leader with a clear digital footprint in the schema_json. The organization schema includes a physical address in South San Francisco, a customer service telephone number, and official logo links. There are no expert claims from unidentifiable ‘gurus’; instead, the site deferentially points to ‘your doctor’ or ‘health care professional’ as the authority. The technical implementation of the heading hierarchy and metadata is clean and professional.
The site avoids bold marketing performance claims like ‘unrivaled success’ and instead uses clinically approved language such as ‘designed to treat’ or ‘high likelihood of coming back.’ These assertions are anchored in the prescribing information and safety data rather than vague performance promises. The site clearly lists ‘serious side effects’ and ‘boxed warnings’ alongside any mention of efficacy, which is the antithesis of marketing bullshit. The disconnect between what is marketed and what is proven is zero due to strict regulatory oversight.
Medical Devices, Pharma & Biotech BS: Genentech (PERJETA) (perjeta.com)
The site perfectly matches the Medical Pharma & Biotech category, focusing on a specific prescription medicine, pertuzumab. The content is heavily regulated, featuring mandatory safety information, indications for use, and clinical dosage protocols characteristic of a major pharmaceutical entity.
When links fail to express hierarchy, the model cannot form clusters or identify primary entities. Examine the Internal Linking Technical Guide and understand how structural signals—not navigation—define your semantic map.
“The score of 13 is exceptionally low. The primary drivers were minor template artifacts (a review count of 1 without proof links) and the high fluff-saturation of the homepage H1. The site achieved 0/15 in Authority Gaps and 1/20 in Semantic Coherence due to the high quality of Genentech's structured data and logical messaging flow.”
Analysis Disclosure & Source Attribution
Snapshot Date: May 30, 2026
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to see how machine logic interprets digital signals.
Machine Perception Notice: This evaluation is generated by machine-read logic (MRL). The AI interprets the “Digital Ghost” of a website (code, metadata, and semantic structures), which may differ from what a human sees at the same moment. This is an automated technical diagnostic and not a statement of fact or human opinion regarding the real-world integrity or legitimacy of the business. Any missing or inaccessible elements in the snapshot are treated as machine-read signals, reflecting AI rendering limitations rather than intentional omission.
Notice to the Evaluated Business: This analysis is part of a non-adversarial audit. The results are intended as professional feedback to help improve machine-readability and authority signals. Any company can use these insights for free. When content is updated, a fresh audit can be requested at any time to reflect the current state.
To All Users: You are encouraged to visit the live site at Genentech (PERJETA) to view the most current version of their content and see directly what the company offers.